Experimental antibodies for Parkinson’s, Alzheimer’s may cause harmful inflammation

Experimental antibodies for Parkinson's, Alzheimer's may cause harmful inflammation
Scientists at Scripps Research find evidence that antibody treatments in clinical trials for neurodegenerative diseases may trigger an inflammatory response that erodes their positive effects. Pictured: Dopaminergic neurons in red and microglia in green. Credit: Lipton laboratory, Scripps Research

A team led by scientists at Scripps Research has made a discovery suggesting that experimental antibody therapies for Parkinson’s and Alzheimer’s have an unintended adverse effect—brain inflammation—that may have to be countered if these treatments are to work as intended.

Experimental antibody treatments for Parkinson’s target abnormal clumps of the protein…

Read more…